New treatment for high blood pressure during pregnancy
Novel Pharmacological Treatment for Preeclampsia
This study is looking at a new medication for preeclampsia, a serious pregnancy condition that raises blood pressure and can affect both moms and babies, to see if a special version of a hormone called serelaxin can help improve blood flow and reduce complications better than the usual treatments that only help with symptoms.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Artemis Biotechnologies LLC NIH-funded |
| Lab location | 1 site (Temple, United States) |
| Project ID | NIH-10758980 on NIH RePORTER |
What this research studies
This research investigates a new pharmacological treatment for preeclampsia, a serious condition that can occur during pregnancy characterized by high blood pressure and potential complications for both the mother and baby. The approach focuses on a novel peptide variant of serelaxin, which has shown promise in animal models for its ability to reduce fibrosis and improve vascular function. By targeting specific receptors, this treatment aims to provide a more effective solution than current palliative measures, which only manage symptoms rather than address the underlying condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant individuals diagnosed with preeclampsia or at high risk for developing the condition.
Not a fit: Patients who are not pregnant or those with other unrelated hypertensive disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment for preeclampsia, significantly improving outcomes for pregnant individuals and their babies.
How similar studies have performed: While serelaxin has shown promise in treating acute heart failure, this specific application for preeclampsia is novel and has not been extensively tested in clinical settings.
Where this research is happening
Temple, United States
- Artemis Biotechnologies LLC — Temple, United States (Active)
Researchers
- Principal investigator: Uddin, Mohammad Nasir — Artemis Biotechnologies LLC
- Study coordinator: Uddin, Mohammad Nasir
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.